In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Corvus Pharmaceuticals Inc. Trade Record

NASDAQ:CRVS Corvus Pharmaceuticals Inc stock gains 29.00% Exit Apr 4, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart CRVS Mar 8, 2017, priceSeries
About Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that plan to initiate a Phase 1/1b clinical trial for adenosine, an immune checkpoint. The company also develops a product candidate, an anti-CD73 monoclonal antibody that inhibits the production of adenosine. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Trade Information
Trade Type
Entry Date
Mar 8, 2017
Entry Price
Sell Date
Apr 4, 2017
Sell Price
Net Gain
Hold Time
19 Trading Days